Key points are not available for this paper at this time.
Introduction: Hypertension (HT) and elevated levels of lipoprotein(a) (Lp(a)) are both significant risk factors for cardiovascular disease. Understanding the relationship between these factors can provide valuable insights into cardiovascular risk stratification. This study aims to analyze the association between Lp(a) levels and HT in hypertensive patients, with a focus on identifying predictors of major adverse cardiovascular events (MACE) within this population. Methods: Patients included in the Argentine Group for the Study of Lp(a) GAELp(a), who had a diagnosis of hypertension were selected for this study. Demographic characteristics, anthropometric variables, cardiovascular risk factors, laboratory variables, and the presence of cardiovascular disease were assessed. Lp(a) levels were measured in mg/dL or nmol/L, with values exceeding 50 mg/dL or 125 nmol/L classified as elevated. Multivariate analysis was conducted to identify predictors of MACE within the study population. Results: A total of 334 hypertensive patients with recorded Lp(a) levels were included in the analysis. Thirty-eight percent of the patients exhibited elevated Lp(a) levels. In the multivariate analysis, predictors of MACE were male sex (OR 2.36, 95% CI 1.33-4.16), current smoker (OR 3.29, 95% CI 1.56-6.96), and type 2 diabetes (OR 2.86, 95% CI 1.43-5.72). However, no significant association was found between MACE and elevated Lp(a) levels. Additionally, it was observed that a substantial proportion (71.56%) of the study population were taking statins. CONCLUSION: This study underscores the importance of considering multiple risk factors, including sex, smoking status, and diabetes, in assessing cardiovascular risk among hypertensive patients. While elevated Lp(a) levels did not emerge as a predictor of MACE in this population, further research is warranted to elucidate the role of Lp(a) in cardiovascular risk stratification.
Arrupe et al. (2024) studied this question.